Taurolidine
| Taurolidine | ||
|---|---|---|
 | ||
| Identifiers | ||
| CAS number | 19388-87-5  | |
| PubChem | 29566 | |
| UNII | 8OBZ1M4V3V | |
| ATC code | B05 | |
| Jmol-3D images | Image 1 | |
| ||
| Properties | ||
| Molecular formula | C7H16N4O4S2 | |
| Molar mass | 284.36 g mol−1 | |
(verify) (what is: / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | ||
| Infobox references | ||
Taurolidine ([bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane) is a drug with antimicrobial and anti-lipopolysaccharide properties. Derived from the amino acid taurine, its immunue modulatory action is reported to be mediated with priming and activation of macrophages and polymorphonuclear leukocytes.[1]
Taurolidine has been used to treat patients with peritonitis and as an antiendoxic agent in patients with systemic inflammatory response syndrome.[2] Additionally, taurolidine demonstrates some anti-tumor properties, with positive results seen in early-stage clinical investigations using the drug to treat gastrointestinal malignancies and tumors of the central nervous system.[2]
Taurolidine has been investigated for the prevention of central venous catheter-related infections, and there is ample evidence that the addition of taurolidine significantly decreases infection rates. [3] [4] [5] [6] [7]
References
- ↑ Watson RW, Redmond HP, Mc Carthy J, Bouchier-Hayes D (September 1995). "Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine". J. Leukoc. Biol. 58 (3): 299–306. PMID 7665985.
- ↑ 2.0 2.1 Jacobi CA, Menenakos C, Braumann C (October 2005). "Taurolidine--a new drug with anti-tumor and anti-angiogenic effects". Anticancer Drugs 16 (9): 917–21. doi:10.1097/01.cad.0000176502.40810.b0. PMID 16162968.
- ↑ Solomon, LR et al (June 2010). "A Randomized Double-Blind Controlled Trial of Taurolidine-Citrate Catheter Locks for the Prevention of Bacteremia in Patients Treated with Hemodialysis". American Journal of Kidney Disease 55 (6): 1060–1068. PMID 20207458.
- ↑ Koldehoff M. and Zakrzewski J.L. (June 2004). "Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients". International Journal of Antimicrobial Agents 24: 491–495. PMID 15519483.
- ↑ Simon A., Ammann R.A., Wiszniewsky G., Bode U., Fleischhack G., and Besuden M.M. (June 2008). "Taurolidine-citrate lock solution significantly reduces CVAD-associated grampositive infections in pediatric cancer patients". BMC Infectious Diseases 8. PMID 18664278.
- ↑ Betjes M.G.H. and van Agteren M. (February 2004). "Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution". Nephrol Dial Transplant 19: 1546–1551. PMID 14993498.
- ↑ Handrup M.M., Moller, J.K., and Schroder, H. (February 2013). "Central Venous Catheters and Catheter Locks in Children With Cancer: A Prospective Randomized Trial of Taurolidine Versus Heparin". Pediatr Blood Cancer 60: 1292–1298. PMID 23417891.